CVS App Brings Home Hard-To-Get CRM Data

Written by Evan Schuman
July 2nd, 2013

When CVS (NYSE:CVS) on Monday (July 1) launched a drug interaction feature on its mobile app, it was a classic example of a deep CRM gift that was positioned—correctly—as a truly useful shopper app. In short, it was one of those rare situations where the interests of the retailer and the shopper were perfectly aligned.

The feature itself is straight-forward. A customer can download all of their CVS prescriptions and then type in any other prescriptions that are being taken plus—and this is critical—any over-the-counter (non-prescription) things they are taking, anything from aspirin or a hay fever pill to Vitamin C to 5-Hour Energy. A consumer can’t actually write anything, but must choose from a pre-populated CVS pulldown menu. That limits their choices, of course. The app then flags any problematic interactions, including pointing out interactions with grapefruit, milk or other common household items.

The potential benefits for the shopper are obvious. The benefits to the chain, though, are equally powerful. CVS now potentially gets three extremely valuable pieces of data: First, a list of prescription drugs presumably being filled by a rival pharmacy. What a clear chance to argue that those particular drugs should be brought over to CVS, an opportunity that doesn’t exist without this information. Secondly, a list of various other things the customer is buying, many of which are likely sold by CVS. Another sales opportunity. Third, given that this is a mobile app, the data is already tied into a specific customer. This sharply enriches the CRM profile for CVS customers—and does it for very few dollars and in a way that seems to be altruistic.

Another advantage is truly an advantage for both the customer and CVS: This (hopefully) complete profile can now be shared with that store’s pharmacist, as it’s put in that customer’s profile. The mobile app can only flag interactions going backwards. Once put into the system, the pharmacist can now be alerted when any new drug is prescribed or when POS detects a purchase of something that interacts with something on the mobile app list. In short, the ability for this to help the customer—and in turn give them an excellent reason to make all of their purchases at CVS—is huge.

Update Note: A CVS agency representative E-mailed that CVS is not currently storing any of the data for any purpose. Although CVS customers are typing in all of this data to a CVS app about potential prescription problematic interactions, none of that data will be accessible to CVS pharmacists. If true, that oddly takes away from one of the most potent reasons for customers to enter this data. If a shopper tells the CVS mobile app that he/she is taking a particular drug and then, two weeks later, is prescribed something that reacts badly with that medication and the pharmacist says nothing because he isn’t allowed to know about it, any adverse reaction could prove legally problematic. Still, the chain is saying–through an agency person–that no data is currently being stored for any reason.

As for privacy, the CVS privacy policy makes this easy. Tried downloading the privacy policy five times on the mobile app. Whereas the drug interaction and every other interactive feature on the app worked perfectly, the app’s link for privacy policy wouldn’t work. Such is life. But the privacy policy did download fine from the Web site.

That policy gives the chain full authority to do anything it wants with this data. It specifically allows personal information to be used to “deliver (to) you customized content, advertising and savings that may be of interest to you” and to “communicate with you regarding updates, offers, and promotions.” Hence, all of those sales efforts are green-lighted.

What about sharing this data with CVS marketers in addition to pharmacists? Not a problem: “CVS Caremark and its subsidiaries may share your personally identifiable information with one another to ensure that your experiences as a customer or user of CVS Caremark Sites is as seamless and enjoyable as possible.” Can this sensitive data be given to random vendors? No problem: “In limited circumstances, CVS Caremark may share your personally identifiable information with third party companies to provide you with technologies, services, or content that may be of interest to you.” They do require permission, but that’s buried within the mandatory terms & conditions fineprint on the app so no problem there.

Kudos to CVS for creating something that could truly help its customers, but at the same time helping CVS revenue and vast data collection. This assumes they ultimately allow their pharmacists to know about the drugs they are encouraging their customers to enter into the CVS app.


Comments are closed.


StorefrontBacktalk delivers the latest retail technology news & analysis. Join more than 60,000 retail IT leaders who subscribe to our free weekly email. Sign up today!

Most Recent Comments

Why Did Gonzales Hackers Like European Cards So Much Better?

I am still unclear about the core point here-- why higher value of European cards. Supply and demand, yes, makes sense. But the fact that the cards were chip and pin (EMV) should make them less valuable because that demonstrably reduces the ability to use them fraudulently. Did the author mean that the chip and pin cards could be used in a country where EMV is not implemented--the US--and this mis-match make it easier to us them since the issuing banks may not have as robust anti-fraud controls as non-EMV banks because they assumed EMV would do the fraud prevention for them Read more...
Two possible reasons that I can think of and have seen in the past - 1) Cards issued by European banks when used online cross border don't usually support AVS checks. So, when a European card is used with a billing address that's in the US, an ecom merchant wouldn't necessarily know that the shipping zip code doesn't match the billing code. 2) Also, in offline chip countries the card determines whether or not a transaction is approved, not the issuer. In my experience, European issuers haven't developed the same checks on authorization requests as US issuers. So, these cards might be more valuable because they are more likely to get approved. Read more...
A smart card slot in terminals doesn't mean there is a reader or that the reader is activated. Then, activated reader or not, the U.S. processors don't have apps certified or ready to load into those terminals to accept and process smart card transactions just yet. Don't get your card(t) before the terminal (horse). Read more...
The marketplace does speak. More fraud capacity translates to higher value for the stolen data. Because nearly 100% of all US transactions are authorized online in real time, we have less fraud regardless of whether the card is Magstripe only or chip and PIn. Hence, $10 prices for US cards vs $25 for the European counterparts. Read more...
@David True. The European cards have both an EMV chip AND a mag stripe. Europeans may generally use the chip for their transactions, but the insecure stripe remains vulnerable to skimming, whether it be from a false front on an ATM or a dishonest waiter with a handheld skimmer. If their stripe is skimmed, the track data can still be cloned and used fraudulently in the United States. If European banks only detect fraud from 9-5 GMT, that might explain why American criminals prefer them over American bank issued cards, who have fraud detection in place 24x7. Read more...

Our apologies. Due to legal and security copyright issues, we can't facilitate the printing of Premium Content. If you absolutely need a hard copy, please contact customer service.